A phase 1b/2 study of Oral HBI-8000 (Tucidinostat) for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma
Latest Information Update: 04 Aug 2023
At a glance
- Drugs Tucidinostat (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Aug 2023 New trial record